[
  {
    "ts": "2025-11-25T13:09:37+00:00",
    "headline": "Is Gilead Sciences Stock Outperforming the Dow?",
    "summary": "Gilead Sciences has outperformed the Dow Jones over the past year, and analysts are upbeat about the healthcare stock's prospects.",
    "url": "https://www.barchart.com/story/news/36303752/is-gilead-sciences-stock-outperforming-the-dow",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "be176957-e5be-3009-8715-dbdf81a2a491",
      "content": {
        "id": "be176957-e5be-3009-8715-dbdf81a2a491",
        "contentType": "STORY",
        "title": "Is Gilead Sciences Stock Outperforming the Dow?",
        "description": "",
        "summary": "Gilead Sciences has outperformed the Dow Jones over the past year, and analysts are upbeat about the healthcare stock's prospects.",
        "pubDate": "2025-11-25T13:09:37Z",
        "displayTime": "2025-11-25T13:09:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/31e98582ac8bd44916a76a1228c3e08e",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Gilead Sciences, Inc_ logo and vials -by Melnikov Dmitriy via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4ZVwOdK61Xg8o5Mr50Lzcw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/31e98582ac8bd44916a76a1228c3e08e.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mZU7yS6z0JfGzyXqezjBuQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/31e98582ac8bd44916a76a1228c3e08e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36303752/is-gilead-sciences-stock-outperforming-the-dow",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-stock-outperforming-dow-130937462.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-25T10:14:55+00:00",
    "headline": "Gilead scoops up a preclinical cancer program",
    "summary": "The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”",
    "url": "https://www.biopharmadive.com/news/gilead-sprint-cancer-deal-trex1/806407/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "7daacbbd-ab83-328d-8974-3d089e3a3cb1",
      "content": {
        "id": "7daacbbd-ab83-328d-8974-3d089e3a3cb1",
        "contentType": "STORY",
        "title": "Gilead scoops up a preclinical cancer program",
        "description": "",
        "summary": "The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”",
        "pubDate": "2025-11-25T10:14:55Z",
        "displayTime": "2025-11-25T10:14:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "BioPharma Dive, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3g5.ulK0vcCqcdyFlYvVw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DH6ljKWVk5FO27mUzvHUcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/gilead-sprint-cancer-deal-trex1/806407/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-scoops-preclinical-cancer-program-101455587.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "SPRINT.ST"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-25T17:53:40+00:00",
    "headline": "Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m",
    "summary": "Gilead’s new immunotherapy asset targets the TREX1 protein, which is a novel target in oncology.",
    "url": "https://www.pharmaceutical-technology.com/news/gilead-sciences-acquires-sprint-biosciences-oncology-trex1-programme/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "c9e59648-ea2e-3992-b3d6-4a44898dd49d",
      "content": {
        "id": "c9e59648-ea2e-3992-b3d6-4a44898dd49d",
        "contentType": "STORY",
        "title": "Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m",
        "description": "",
        "summary": "Gilead’s new immunotherapy asset targets the TREX1 protein, which is a novel target in oncology.",
        "pubDate": "2025-11-25T17:53:40Z",
        "displayTime": "2025-11-25T17:53:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/39fb2a8cbea600d3e8fc595da77a906e",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Sprint Biosciences has sold its oncology programme to Gilead Sciences",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D55ZgCI5Tc047hgF7XWslg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/39fb2a8cbea600d3e8fc595da77a906e.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QHjbAcZRQtNU.Z5dL8JdOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/39fb2a8cbea600d3e8fc595da77a906e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/gilead-sciences-acquires-sprint-biosciences-oncology-trex1-programme/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-snaps-sprint-trex1-immunotherapy-175340597.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]